Author Search Results :: UTM Library Massive Scholar Tracking

1

$Effect of β-blocker therapy on the level soluble ST2 protein in the blood serum in patients with heart failure with preserved and mildly reduced ejection fraction$

Effect of β-blocker therapy on the level soluble ST2 protein in the blood serum in patients with heart failure with preserved and mildly reduced ejection fraction by E. V. Grakova, K. V. Kopeva, A. T. Teplyakov, M. V. Soldatenko, T. E. Suslova, V. V. Kalyuzhin

Published 2022-04-01

Get full text

Article

2

EARLY MARKERS OF PROGRESSION OF HEART FAILURE AND APOPTOSIS: THEIR ROLE IN PREDICTING THE RISK OF ADVERSE CARDIOVASCULAR EVENTS IN PATIENTS WITH PRIOR MYOCARDIAL INFARCTION by A. T. Teplyakov, E. V. Grakova, E. N. Berezikova, S. N. Shilov, K. V. Kopeva, V. V. Kalyuzhin

Published 2016-03-01

Get full text

Article

3

The prognostic value of the NT-proBNP biomarkers and Fas ligand in assessing the risk of cardiotoxicity of anthracycline chemotherapy by A. T. Teplyakov, S. N. Shilov, A. A. Popova, E. N. Berezikova, M. N. Neupokoeva, E. V. Grakova, K. V. Kopeva

Published 2019-03-01

Get full text

Article

4

$Predictors of an adverse course of heart failure with preserved left ventricular ejection fraction in patients with obstructive sleep apnea syndrome$

Predictors of an adverse course of heart failure with preserved left ventricular ejection fraction in patients with obstructive sleep apnea syndrome by A. T. Teplyakov, A. V. Yakovlev, S. N. Shilov, N. F. Yakovleva, E. N. Berezikova, E. V. Grakova, K. V. Kopeva, S. D. Mayanskaya

Published 2021-07-01

Get full text

Article

5

$Heart failure with preserved ejection fraction: the role of microvascular dysfunction$

Heart failure with preserved ejection fraction: the role of microvascular dysfunction by K. V. Kopeva, A. V. Mochula, A. N. Maltseva, E. V. Grakova, V. V. Shipulin, A. M. Gusakova, K. V. Zavadovsky

Published 2023-01-01

Get full text

Article

6

$Role of humoral markers in the pathogenesis of heart failure with preserved ejection fraction in patients with non-obstructive coronary artery disease$

Role of humoral markers in the pathogenesis of heart failure with preserved ejection fraction in patients with non-obstructive coronary artery disease by E. V. Grakova, K. V. Kop’eva, A. M. Gusakova, A. V. Smorgon, A. N. Maltseva, A. V. Mochula, K. V. Zavadovsky

Published 2022-11-01

Get full text

Article

7

Chronic Heart Failure in Patients with Arterial Hypertension Associated with Obstructive Sleep Apnea Syndrome: Possible Options to Pathogenetic Therapy by A. V. Yakovlev, S. N. Shilov, E. N. Berezikova, N. F. Yakovleva, A. T. Teplyakov, E. V. Grakova, K. V. Kopeva, I. A. Efremov

Published 2021-07-01

Get full text

Article

8

$Coronary flow reserve in patients with heart failure with preserved ejection fraction$

Coronary flow reserve in patients with heart failure with preserved ejection fraction by A. V. Mochula, K. V. Kop’eva, A. N. Maltseva, E. V. Grakova, M. O. Gulya, А. M. Gusakova, K. V. Zavadovsky

Published 2022-03-01

Get full text

Article

9

Pharmacogenetics in treatment of anthracycline-induced cardiotoxicity in women without prior cardiovascular diseases by E. V. Grakova, K. V. Kopeva, S. N. Shilov, E. N. Berezikova, A. A. Popova, M. N. Neupokoeva, E. T. Ratushnyak, V. V. Kalyuzhin, A. T. Teplyakov

Published 2023-01-01

Get full text

Article

10

Cardioprotective effects of alendronate bisphosphonate in patients with ischemic heart disease associated with type 2 diabetes mellitus and osteoporosis by S. N. Shilov, E. N. Berezikova, A. A. Popova, E. N. Samsonova, A. T. Teplyakov, E. V. Grakova, K. V. Kopeva, A. V. Molokov, I. V. Yakovleva

Published 2021-05-01

Get full text

Article

11

The effect of bisphosphonate therapy on reducing the risk of cardiovascular complications associated with chronic heart failure, type 2 diabetes and osteoporosis in postmenopausal... by A T Teplyakov, E N Berezikova, S N Shilov, A A Popova, E N Samsonova, I V Yakovleva, A V Molokov, E V Grakova, K V Kopeva

Published 2019-10-01

Get full text

Article

12

Association of impaired myocardial flow reserve with risk factors for cardiovascular diseases in patients with nonobstructive coronary artery disease by A. N. Maltseva, K. V. Kop’eva, A. V. Mochula, M. O. Gulya, O. N. Dymbrylova, E. V. Grakova, A. A. Boshchenko, K. V. Zavadovsky

Published 2023-03-01

Get full text

Article

13

$Prognostic value of hypoxia-inducible factor-1 alpha gene polymorphism in patients with heart failure with preserved ejection fraction and obstructive sleep apnea$

Prognostic value of hypoxia-inducible factor-1 alpha gene polymorphism in patients with heart failure with preserved ejection fraction and obstructive sleep apnea by A. V. Yakovlev, R. S. Chernyshev, K. S. Sakhonchik, S. N. Shilov, E. V. Grakova, K. V. Kop’eva, A. T. Teplyakov, I. A. Efremov, M. S. Kessler, N. F. Yakovleva, I. A. Grebenkina

Published 2022-08-01

Get full text

Article

14

Promising directions in the treatment of chronic heart failure: improving old or developing new ones? by V. V. Kalyuzhin, A. T. Teplyakov, I. D. Bespalova, E. V. Kalyuzhina, N. N. Terentyeva, E. V. Grakova, K. V. Kopeva, V. Yu. Usov, N. P. Garganeeva, O. A. Pavlenko, Yu. V. Gorelova, A. V. Teteneva

Published 2022-10-01

Get full text

Article

15

Diuretic resistance in patients with chronic heart failure: mechanisms, prevention, and treatment by V. V. Kalyuzhin, A. T. Teplyakov, I. D. Bespalova, E. V. Kalyuzhina, N. N. Terentyeva, I. K. Livshits, V. L. Ostanko, E. V. Grakova, K. V. Kopeva, V. Yu. Usov, N. P. Garganeeva, Yu. V. Gorelova

Published 2022-07-01

Get full text

Article

16

Osteoprotegerin is a new independent predictor of the progression of cardiovascular pathology: chronic heart failure associated with type 2 diabetes and osteoporosis by A. T. Teplyakov, E. N. Berezikova, S. N. Shilov, A. A. Popova, I. V. Yakovleva, A. V. Molokov, E. V. Grakova, K. V. Kopeva, A. V. Svarovskaya, O. V. Garmaeva, Yu. Yu. Torim, E. I. Stepachev, V. V. Kalyuzhin

Published 2018-12-01

Get full text

Article

Effect of β-blocker therapy on the level soluble ST2 protein in the blood serum in patients with heart failure with preserved and mildly reduced ejection fraction by E. V. Grakova, K. V. Kopeva, A. T. Teplyakov, M. V. Soldatenko, T. E. Suslova, V. V. Kalyuzhin

EARLY MARKERS OF PROGRESSION OF HEART FAILURE AND APOPTOSIS: THEIR ROLE IN PREDICTING THE RISK OF ADVERSE CARDIOVASCULAR EVENTS IN PATIENTS WITH PRIOR MYOCARDIAL INFARCTION by A. T. Teplyakov, E. V. Grakova, E. N. Berezikova, S. N. Shilov, K. V. Kopeva, V. V. Kalyuzhin

The prognostic value of the NT-proBNP biomarkers and Fas ligand in assessing the risk of cardiotoxicity of anthracycline chemotherapy by A. T. Teplyakov, S. N. Shilov, A. A. Popova, E. N. Berezikova, M. N. Neupokoeva, E. V. Grakova, K. V. Kopeva

Predictors of an adverse course of heart failure with preserved left ventricular ejection fraction in patients with obstructive sleep apnea syndrome by A. T. Teplyakov, A. V. Yakovlev, S. N. Shilov, N. F. Yakovleva, E. N. Berezikova, E. V. Grakova, K. V. Kopeva, S. D. Mayanskaya

Heart failure with preserved ejection fraction: the role of microvascular dysfunction by K. V. Kopeva, A. V. Mochula, A. N. Maltseva, E. V. Grakova, V. V. Shipulin, A. M. Gusakova, K. V. Zavadovsky

Role of humoral markers in the pathogenesis of heart failure with preserved ejection fraction in patients with non-obstructive coronary artery disease by E. V. Grakova, K. V. Kop’eva, A. M. Gusakova, A. V. Smorgon, A. N. Maltseva, A. V. Mochula, K. V. Zavadovsky

Chronic Heart Failure in Patients with Arterial Hypertension Associated with Obstructive Sleep Apnea Syndrome: Possible Options to Pathogenetic Therapy by A. V. Yakovlev, S. N. Shilov, E. N. Berezikova, N. F. Yakovleva, A. T. Teplyakov, E. V. Grakova, K. V. Kopeva, I. A. Efremov

Coronary flow reserve in patients with heart failure with preserved ejection fraction by A. V. Mochula, K. V. Kop’eva, A. N. Maltseva, E. V. Grakova, M. O. Gulya, А. M. Gusakova, K. V. Zavadovsky

Pharmacogenetics in treatment of anthracycline-induced cardiotoxicity in women without prior cardiovascular diseases by E. V. Grakova, K. V. Kopeva, S. N. Shilov, E. N. Berezikova, A. A. Popova, M. N. Neupokoeva, E. T. Ratushnyak, V. V. Kalyuzhin, A. T. Teplyakov

Cardioprotective effects of alendronate bisphosphonate in patients with ischemic heart disease associated with type 2 diabetes mellitus and osteoporosis by S. N. Shilov, E. N. Berezikova, A. A. Popova, E. N. Samsonova, A. T. Teplyakov, E. V. Grakova, K. V. Kopeva, A. V. Molokov, I. V. Yakovleva

Association of impaired myocardial flow reserve with risk factors for cardiovascular diseases in patients with nonobstructive coronary artery disease by A. N. Maltseva, K. V. Kop’eva, A. V. Mochula, M. O. Gulya, O. N. Dymbrylova, E. V. Grakova, A. A. Boshchenko, K. V. Zavadovsky

Promising directions in the treatment of chronic heart failure: improving old or developing new ones? by V. V. Kalyuzhin, A. T. Teplyakov, I. D. Bespalova, E. V. Kalyuzhina, N. N. Terentyeva, E. V. Grakova, K. V. Kopeva, V. Yu. Usov, N. P. Garganeeva, O. A. Pavlenko, Yu. V. Gorelova, A. V. Teteneva

Diuretic resistance in patients with chronic heart failure: mechanisms, prevention, and treatment by V. V. Kalyuzhin, A. T. Teplyakov, I. D. Bespalova, E. V. Kalyuzhina, N. N. Terentyeva, I. K. Livshits, V. L. Ostanko, E. V. Grakova, K. V. Kopeva, V. Yu. Usov, N. P. Garganeeva, Yu. V. Gorelova

Search Tools: